Eve Holding is a pre-revenue eVTOL developer with zero sales, relying on Embraer's backing to fund an aggressive R&D program that has consumed over $810M in cumulative losses.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.16+11.0% vs -$0.18 | — vs $200,000 |
Q3 2026 Aug 4, 2026 | -$0.10+45.7% vs -$0.18 | — vs — |
Q2 2026 May 5, 2026 | -$0.20-33.3% vs -$0.15 | — vs — |
Q2 2026 Mar 16, 2026 | -$0.18-28.6% vs -$0.14 | — vs $2M |
EVE NYSE: EVEX expects its cash resources to support operations through 2028 without new funding as it advances development of its electric vertical takeoff and landing aircraft, executives said on the company's third-quarter 2026 earnings call.
Eve Holding, Inc. ( EVEX ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Lucio Aldworth - Director of Investor Relations Johann Christian Jean Bordais - Chief Executive Officer Eduardo Couto - Chief Financial Officer Marcelo Basile - Head of Tests Conference Call Participants Andres Sheppard-Slinger - Cantor Fitzgerald & Co., Research Division Savanthi Syth - Raymond James & Associates, Inc., Research Division Adam Samuelson - Jefferies LLC, Research Division Amit Dayal - H.C. Wainwright & Co, LLC, Research Division Andre Madrid - BTIG, LLC, Research Division Austin Moeller - Canaccord Genuity Corp., Research Division Patrick McCann - D.
Windward Bio Group AG seeks to raise development capital in a U.S. IPO to advance its clinical-stage pipeline. WWB's lead asthma drug, WIN378, has shown promising Phase 2/3 results; pivotal trial data is expected by mid-2027. The company boasts a top-tier management team with a strong track record and backing from prominent institutional investors.
MELBOURNE, Fla. , Nov. 5, 2026 /PRNewswire/ -- Eve Holding, Inc. ("Eve") (NYSE: EVEX / B3: EVEB31) reports its third quarter 2026 earnings results.
Benchmark EVEX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Eve Holding, Inc. (EVEX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.85 | $644.36M | -2.89 | — | — | -535.24% | — | |
| $5.93 | $5.83B | -8.42 | 39183.09% | -462.84% | -40.04% | — | |
| $4.44 | $3.37B | -4.34 | — | -11589.86% | -40.74% | — | |
| $3.09 | $33.66M | -0.49 | 220.58% | -301.49% | -253.36% | — | |
| $173.40 | $137.05B | 17.69 | 34.5% | 8.07% | 126.96% | 0.25% | |
| $112.76 | $5.71B | -19.37 | 140.89% | -14.49% | -6.64% | — |
Eve Holding, Inc. (EVEX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Eve Holding, Inc. (EVEX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
May 22, 2026·SEC
May 5, 2026·SEC
Get notified when EVEX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Eve Holding, Inc. (EVEX) stock FAQ — growth, dividends, profitability & financials explained
No. Eve Holding, Inc. (EVEX) reported a net loss of $225.0M over the trailing twelve months.
Eve Holding, Inc. (EVEX) had a return on equity (ROE) of -535.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
Eve Holding, Inc. (EVEX) had negative free cash flow of $202.2M over the trailing twelve months.
